BioCentury

8:00 AM GMT, Nov 16, 2015
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Anifrolumab: Phase II data

A double-blind, international Phase II trial in 305 patients with seropositive moderate to severe SLE showed that 300 mg IV anifrolumab every 4 weeks met the primary endpoint of a greater proportion of patients achieving an

Read the full 361 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.